Thomas E. Hutson
Impact in
- Pulmonary and Respiratory Medicine top 0.01%
- Renal cell carcinoma treatment
- Cancer Research top 0.05%
- Cancer Genomics and Diagnostics
- Cancer, Hypoxia, and Metabolism
Papers in
-
- Renal cell carcinoma treatment 207
- Prostate Cancer Treatment and Research 22
-
- Cancer Genomics and Diagnostics 88
- Co-authors
- Robert J. Motzer (93 shared papers)Stéphane Oudard (21 shared papers)Robert A. Figlin (60 shared papers)Ronald M. Bukowski (42 shared papers)Sylvie Négrier (12 shared papers)Cezary Szczylik (19 shared papers)Bernard Escudier (59 shared papers)M. Dror Michaelson (33 shared papers)
- Journals
- Journal of Clinical Oncology (114 papers)Clinical Genitourinary Cancer (22 papers)Annals of Oncology (19 papers)Cancer (12 papers)The Oncologist (9 papers)
- Partner nations
- United StatesFranceItaly
In The Last Decade
Thomas E. Hutson
282 papers receiving 24.3k citations
Thomas E. Hutson's Hit Papers
Peers
Comparison fields: 5 of 122
- Pulmonary and Respiratory Medicine 15.6k
- Cancer Research 6.2k
- Oncology 5.5k
- Molecular Biology 10.0k
- Hepatology 467
Countries citing papers authored by Thomas E. Hutson
This map shows the geographic impact of Thomas E. Hutson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas E. Hutson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas E. Hutson more than expected).
Fields of papers citing papers by Thomas E. Hutson
This network shows the impact of papers produced by Thomas E. Hutson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas E. Hutson. The network helps show where Thomas E. Hutson may publish in the future.
Co-authors
The 25 scholars most cited alongside Thomas E. Hutson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 291 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma Hit paper breakdown → | 2007 | 4485 |
| 2 | Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma Hit paper breakdown → | 2007 | 3815 |
| 3 | Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Hit paper breakdown → | 2008 | 2345 |
| 4 | Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2009 | 1719 |
| 5 | Phase 3 trial of everolimus for metastatic renal cell carcinoma Hit paper breakdown → | 2010 | 905 |
| 6 | Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial Hit paper breakdown → | 2009 | 866 |
| 7 | Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial Hit paper breakdown → | 2015 | 696 |
| 8 | Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial Hit paper breakdown → | 2013 | 544 |
| 9 | Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy Hit paper breakdown → | 2011 | 476 |
| 10 | Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2009 | 379 |
| 11 | Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial Hit paper breakdown → | 2013 | 321 |
| 12 | 2008 | 320 | |
| 13 | Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2013 | 295 |
| 14 | 2011 | 235 | |
| 15 | 2009 | 229 | |
| 16 | 2012 | 210 | |
| 17 | 2012 | 205 | |
| 18 | 2019 | 168 | |
| 19 | 2008 | 162 | |
| 20 | 2007 | 159 |
About Thomas E. Hutson
Thomas E. Hutson is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology, Oncology and Economics and Econometrics, having authored 291 papers that have together received 24.7k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (207 papers), Cancer Genomics and Diagnostics (88 papers), Renal and related cancers (59 papers), Economic and Financial Impacts of Cancer (27 papers), Bladder and Urothelial Cancer Treatments (25 papers), Cancer Immunotherapy and Biomarkers (23 papers), Prostate Cancer Treatment and Research (22 papers) and Multiple and Secondary Primary Cancers (14 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (15.6k citations), Cancer Research (6.2k citations), Oncology (5.5k citations), Molecular Biology (10.0k citations) and Hepatology (467 citations). Thomas E. Hutson has collaborated with scholars based in United States, France and Italy. Frequent co-authors include Robert J. Motzer, Stéphane Oudard, Robert A. Figlin, Ronald M. Bukowski, Sylvie Négrier, Cezary Szczylik, Bernard Escudier, M. Dror Michaelson, Piotr Tomczak and Sindy T. Kim. Their work appears in journals such as Journal of Clinical Oncology, Clinical Genitourinary Cancer, Annals of Oncology, Cancer and The Oncologist.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.